Here are the 10-K annual reports from AptarGroup, Inc. (ATR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ATR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATR filings page.
AptarGroup, Inc. is a global supplier of dosing, dispensing and protection technologies for pharmaceuticals, beauty, personal care, home care, food and beverage products. The company operates three segments: Pharma, Beauty and Closures.
In 2025, Pharma generated about 46% of net sales and 69% of adjusted EBITDA (excluding non-allocated corporate costs), supplying nasal spray pumps, inhaler valves, injectable elastomer components, active material science solutions and digital health tools. Beauty contributed roughly 35% of net sales with pumps, airless systems and valves for fragrance, skincare, cosmetics and personal care. Closures represented about 19% of net sales, focusing on dispensing closures for food, beverage and personal care applications.
Aptar is geographically diversified, with 57 manufacturing facilities worldwide and approximately 14,000 employees, and no single customer exceeding 4% of 2025 net sales. The company emphasizes sustainability, including science-based emissions targets, recyclable and PCR-based packaging solutions, and multiple external recognitions for environmental and social performance. Recent portfolio moves include acquiring Sommaplast for $27 million, increasing ownership in BTY to 80% for about $29 million, and a 40% stake in Goldrain for about $99 million.
Key risks highlighted include macroeconomic weakness, geopolitical tensions and tariffs, supply chain and single‑source material dependence, cybersecurity threats, foreign currency volatility, labor relations, environmental and packaging regulations, tax changes, climate-related impacts and exposure to routine litigation and regulatory oversight.